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Determining HIV-1 Quasispecies Genomic Variability to Optimize gRNA Excision 
Using the CRISPR/Cas9 Gene Editing System 
Matthew F. DeSimone 
 
 
 
In light of the global human immunodeficiency virus type 1 (HIV-1) epidemic, 
numerous attempts have been made to combat HIV-1 and cure patients of an otherwise 
deadly infection. While improving survival rates among HIV-1 infected patients, highly 
active retroviral therapy (HAART) and related therapies are at best a stalling measure due 
to the inevitable reemergence of escape virus from latently infected cellular reservoirs. 
Gene editing technologies hold the promise to permanently excise integrated virus from 
the genome. The general aim of this research was to thoroughly consider the current state 
of both Next Generation Sequencing (NGS) and the CRISPR/Cas9 gene-editing 
technologies and propose a method of optimization for their application to excise HIV-1 
proviral DNA from infected host cell targets. To do so, a bioinformatic pipeline was 
designed and implemented that utilized novel NGS sequence data from HIV-1 infected 
patients to determine all targetable regions of viral DNA in all quasispecies, and quantify 
the excision probabilities using the known binding affinities of the CRISPR/Cas9 gene-
editing system. The exact gRNA guides have been identified that can facilitate optimized 
cleavage of these sites using the CRISPR/Cas9 system for proviral excision. With this 
information, the number and sequences of gRNAs required to excise the patient-specific 
HIV-1 quasispecies has been determined. These results represent a step along the path 
towards a sterilizing cure that can thoroughly eradicate HIV/AIDS.
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Chapter 1: Introduction to the CRISPR/Cas9 Genome Editing System 
Introduction 
CRISPR-Cas systems are composed of clustered regularly interspaced short 
palindromic repeats (CRISPR) and associated proteins (Cas) that offer bacteria and some 
archaea robust immunity from foreign elements such as bacteriophages [1]. CRISPR loci 
are made up of short, partially palindromic DNA repeats that exist in regular intervals 
and alternate repeated elements and variable sequences that are usually flanked by Cas 
genes [1]. These Cas genes encode an expansive classification of proteins that include 
functional domains characteristic of nucleases, helicases, polymerases, and 
polynucleotide-binding proteins [2]. Until 2005, the biological function of these systems 
remained largely unknown until the discovery that the variable sequences, or CRISPR 
spacers, of the system were homologous to segments of genetic content of viruses and 
plasmids [1]. It was then deduced that these systems utilized sequence-specific, RNA-
mediated, targeting of excerpts of DNA, and sometimes RNA, to act as an adaptive 
immune system that can target the DNA of viruses foreign to a given bacteria [1]. Having 
to adapt in often harsh ecosystems, microbes evolved various strategies of survival from 
infection by foreign genetic material - chief among them being the CRISPR/Cas system. 
Due to the continual threat of extracellular DNA entering the cell by means of 
transduction, conjugation, and transformation, the system emerged in microbes as an 
inheritable DNA-encoded immunity to some viruses and plasmids by targeting their vital 
nucleic acids utilizing specific recognition sequences [3]. The CRISPR family of DNA 
repeats can be found in roughly 90% of archaeal and 40% of bacterial genomes [3].  
The CRISPR repeats and their associated Cas proteins that constitute the 
CRISPR/Cas system, while simple in function, manifest very differently. Six “core” Cas 
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genes have been discovered, including two universal genes, cas1 and cas2, that are 
observed in all CRISPR/Cas systems [3]. In addition, the size of CRISPR repeats and 
spacers have been determined to be variable as well, with each being observed between 
23 to 47 basepairs (bp) and 21 to 72 bp, respectively [3]. Repeat sequences of the 
CRISPR locus are also highly variable between microbial species but are usually highly 
conserved within a locus [4]. These repeat sequences are somewhat palindromic, which 
has suggested that they can form highly conserved and stable secondary structures [5]. 
Most loci contain fewer than 50 repeat-spacer units, although it has been observed that 
this number can reach up to 375 [3]. Microbes may even possess up to 18 CRISPR loci 
[3]. These loci are usually found on the chromosome, but some have been identified in 
microbial plasmids [3]. The most diverse component of the CRISPR/Cas system, 
however, has been identified in the spacer sequences, even between similar strains [3]. 
This hyperdiversity between even closely related microbes was explained in 2005 when 
in silico studies determined that these spacer sequences closely resembled 
extrachromosomal elements, such as viruses and plasmids, and were adaptive “targets” 
that provided the microbe with immunity from foreign genetic material [3]. An example 
of the diverse manifestation of the CRISPR/Cas system can be seen in the four systems of 
Streptococcus thermophilus DGCC7710, which can be seen in Figure 1. 
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Figure 1: The four CRISPR/Cas systems of Streptococcus thermophilus DGCC7710. 
The figure above, based on Figure 1 from Philippe Horvath and Rodolphe Barrangou’s 
“CRISPR/Cas, the Immune System of Bacteria and Archaea,” portrays the four 
CRISPR/Cas systems in Streptococcus thermophilus DGCC7710 [3]. Each system is 
shown with their gene organization at the top with Cas genes in gray and respective 
repeat-spacer arrays in black. From this, the diversity of the CRISPR/Cas system is 
apparent. 
 
 
 
Although presented in many forms, the CRISPR system CRISPR nuclease Cas9 
of Streptococcus pyogenes is the most notable of the family, as it has been used to 
pioneer a number of new techniques in molecular biology [6]. Cas9 serves as an 
exclusive type II CRISPR locus gene and exhibits sequence homology and length 
variability but with similar domain architecture throughout [1]. It offers the ability to 
multiplex targets by use of short (20 nucleotide) guide RNAs (gRNAs) that specify target 
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DNA via Watson-Crick base pairing, but with the requirement of protospacer-adjacent 
motifs (PAM) sequences that flank the 3’ end of DNA target sites to attract the search 
mechanism of Cas9 [6].  
The exact physiological mechanism that yields sequence-specific targeting and 
removal of viral and plasmid genetic material has not yet been fully described [3]. 
However, we do know that at the direction of gRNAs, the Cas9 RuvC and HNH nuclease 
domains undergo structural change that will later form a bilobed architecture that features 
target recognition and nuclease lobes [7]. The nuclease lobe is comprised of the RuvC 
and HNH nuclease domains, along with a C-terminal region, and is responsible for the 
cleavage of double stranded DNA complementary to the gRNA [7]. This functionality 
has been confirmed, exhaustively, through experiments where spacer content, the 
biological parallel to gRNA, is genetically engineered and phage resistance or 
vulnerability has been shown with added or removed spacers, respectively [3]. The 
targeting of the system was elaborated upon in 2007 when it was discovered that bacteria 
commonly alter their CRISPR loci by incorporating into the leader end of the locus new 
repeat-spacer units that designate the targeting of another viral strain [3]. The same 
studies suggested that the integrated sequences originate from viral nucleic acid [3]. 
Regardless of the targeting and the physiological mechanism behind cleavage, after being 
cut by the CRISPR/Cas system DNA often exhibits one of two major courses of repair in 
either the error-prone nonhomologous end joining (NHEJ) or high-fidelity homology-
directed repair (HDR), both of which can be leveraged to obtain desired editing outcomes 
[8]. Double-stranded breaks being re-ligated by NHEJ in the absence of a repair template 
often leaves insertion/deletion (indel) mutations that can cause gene knockouts from 
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frameshifts or premature stop codons [8]. HRD, on the other hand, can make explicit 
modifications to a target locus if exposed to an exogenous repair template [8]. 
Obtaining sequence-specific cleavage of double stranded DNA is achieved using 
the targeting specificity of the CRISPR/Cas9 system in the presence of gRNA targets [9]. 
Patrick Hsu, et al., have characterized this targeting specificity in over 700 guide RNA 
variants in 293T and 293FT human cells in “DNA targeting specificity of RNA-guided 
Cas9 nucleases.” To evaluate the magnitude of binding affinity for sequences 
complementary to gRNAs, Hsu, et al., assessed the cleavage activity yielded from a 
single gRNA on multiple genomic off-target loci with sequence similarity. They created a 
large-scale experiment to test mismatched guide sequences by developing a gRNA 
testing assay that generated expression cassettes encoding U6-driven gRNAs using PCR 
and transfected the resulting amplicons [9]. Deep sequencing of the regions flanking each 
target site was then performed for two independent biological replicates before applying a 
binomial model to differentiate true indel events from cleavage and those from NHEJ 
misrepair - reaching a 95% confidence interval for all reported NHEJ frequencies [9]. 
From over 450 gRNAs targets to four target sites within the human EMX1 locus, they 
evaluated and quantified cleavage activity at the on-target genomic locus with all possible 
single-nucleotide substitutions in the positions 1-19 preceding the required NGG PAM 
sequence. In doing so, they determined that CRISPR/Cas9 system cleavage is sequence- 
and locus-dependent and that the system permits mismatches between guide RNA and 
targeted DNA at different positions depending on the number, position, and distribution 
of mismatches [9]. They concluded that most of the sequence specificity is determined by 
the PAM-proximal 8-12 basepairs of the gRNA, with PAM-distal sequences still 
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contributing to the overall binding affinity, but to a lesser extent [9]. They then used this 
information as the basis for a scoring algorithm that quantified the exact effect of 
mismatch location, density, and identity on binding affinity, from each position of a 
gRNA target [9]. The development of this algorithm has since been tested on genome-
wide targets to determine that over 50% of all cutting variance is attributable to the 
promiscuity of gRNA binding, and now serves as a standard for gRNA targeting in 
genome engineering applications [9]. 
Experimental and Therapeutic Application of the CRISPR/Cas System 
With the capabilities of the CRISPR/Cas system to selectively target nucleotide 
sequences and effectively remove them from a genome, great effort has been put into 
leveraging the unique biological function in genome modification and engineering. 
Although the technology is still relatively new, it has already shown tremendous promise 
with applications in biology, biotechnology, pharmaceuticals, bioproducts, genetic 
engineering, and a number of other areas. Due to the ease of retargeting Cas9 by only 
changing a short RNA sequence, it has been used for large-scale unbiased genome 
perturbation experiments that probe gene function and elucidate genetic variants [6]. 
CRISPR/Cas9 excision also presents the opportunity to be scaled, as it has been used 
with multiple gRNAs to achieve large-fragment deletion and insertion [7]. Furthermore, 
the system has been exploited to repress and activate gene expression in both bacteria and 
mammalian cells: repression by targeting the promoter sequences of genes and activation 
by fusing of Cas9 to activation domains [1]. In addition, the attachment of functional 
domains, such as recombinases, methylases, and histone-modifying enzymes to 
CRISPR/Cas9 can hybridize the uses of the system and expand its application to develop 
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new opportunities for the technology [1]. For example, GFP-tagged Cas9 has been used 
in the imaging of telomeres and coding genes in living cells, which could provide vital 
information around the spatiotemporal organization and dynamics of chromatin in 
regulating genome function [7]. Genotyping has also been improved by using the 
CRISPR/Cas9 system, as a number of bacteria, including Mycobacterium, Yersinia, 
Corynebacterium, Pseudomonas, Legionella, Streptococci, Escherichia, Salmonella, and 
Lactobacillus, have been characterized using the technology [1]. In a similar vein, the 
system also has facilitated the development of lentivirus-based gRNA libraries that cover 
nearly all mouse and human genes [7]. The CRISPR/Cas system can even be used as 
means to prevent horizontal gene transfer [1]. 
The CRISPR/Cas9 system has also been used to achieve efficient genome editing 
in human cell lines, bacteria, zebrafish, yeast, mice, fruit flies, roundworms, rats, 
common crops, pigs, and monkeys [6]. Four genes have been disrupted in rats at an 
efficiency of 24%, five genes have been targeted in mice at an efficiency of 75%, five 
genes have been targeted in mouse embryonic stem cells at an efficiency of 10%, and five 
genes have been target in somatic cells of zebrafish at comparably high efficiency, all 
simultaneously [7]. CRISPR/Cas9 and associated gRNAs transcribed in vitro from 
plasmids have already been microinjected into one-cell embryos of zebrafish, fruit flies, 
mice, rats, pigs, and monkeys to produce genetically modified animals [7]. Through 
direct microinjection, mutagenesis at target sites was observed in up to 88% of fruit flies, 
with 33% of the mutations being stably transmitted to their progeny [10]. The purified 
Cas9 protein complex with gRNAs has also been microinjected into embryos to generate 
knockout mice and zebrafish [7]. Plants are also included in the list of genetically 
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engineered products by the Cas9 and gRNA system; polyethylene glycol and 
Agrobacterium delivery into wheat, rice, sorghum, tobacco, and thale cress, all have been 
well documented [7]. It is thought that the modification of crop genomes through 
utilization of the CRISPR/Cas9 system will improve crop quality and improve future 
breeding techniques by specifying phenotypes or genetically encoding disease resistance 
[10]. Although implying a host of ethical considerations, it is speculated that in the future 
the genome-editing tool could even bring about the possibility of designing animal, plant, 
human, and any other genotypes at will [7]. 
The clinical applications of the CRISPR/Cas9 system have been extensively 
explored. Still in its infancy, the gene-editing system has already been proposed as a 
feasible approach to modifying human embryos and has been applied, although with 
significant hurdles, to non-viable embryos to modify a gene that causes β-thalassaemia, a 
potentially fatal blood disorder [11]. Consequentially, the technology has also ignited one 
of the fiercest ethical debates surrounding gene-editing and it should come as no surprise 
that it remains under intense regulation [11].  In spite of the technology’s youth and 
regulation, CRISPR/Cas9 has still been utilized to correct genetic diseases in mice [10] 
and in intestinal stem cell organoids of cystic fibrosis patients [7]. Evidence from an adult 
mouse model of human hereditary tyrosinemia disease also suggests that the 
CRISPR/CAS9 system has corrected the Fah mutation, along with its symptoms [7]. 
Muscular dystrophy, which otherwise has no effective treatment in any form, has also 
been prevented in mice using the CRISPR/Cas9 system to correct the dystrophin gene 
(Dmd) mutations in the germline of mdx mice, suggesting that treatment is not too far off 
in humans [12]. The development of the CRISPR/Cas9 system has clinical relevance in 
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other forms, too. In addition to its direct impact to some cures, it has also provided 
researchers with an efficient and reliable approach to provide cynomolgus monkeys, a 
genetically modified model species for biomedical research testing, by coinjection of 
CRISPR/Cas9 and associated gRNAs into one-cell-stage embryos [13]. CRISPR/Cas9 
has also already been used to screen human cells for genes, with both negative and 
positive selection, on a genome-wide scale with a high level of consistency [14]. Most 
significantly, however, is the possibility to eradicate new/acute viral infections [15], 
which will be considered further in this publication in the context of HIV-1. Despite the 
development of therapies to manage these viral infections, there are otherwise no 
effective strategies to cure them [15]. With potential such as that, in a considerably recent 
discovery, there is no question that resources will be poured into the advancement of the 
CRISPR/Cas9 gene-editing system. As the technology continues to move forward in 
development, more certainty around the cleavage mechanism must be obtained, and more 
robust delivery techniques must also be identified, in order to continue to increase the 
number and quality of clinical applications. 
Challenges and, Opportunities of the CRISPR/Cas System 
Although the CRISPR/Cas9 system already presents a significant number of 
opportunities, challenges do exist that leave the future of the system uncertain. Most 
notably, the underlying physiological mechanisms of CRISPR/Cas9 cleavage are still 
unclear [7]. Not unrelated, in some cases CRISPR/Cas9 cleavage of genomic sequences 
will also lead to cell death, presumably due to chromosomal lesions that can only be 
repaired by replacing the removed target sequence [1]. In addition, CRISPR/Cas9 
cleavages are vulnerable to the possibility of undesired nonhomologous end joining 
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repair, which might reintroduce excised targets [1]. The CRISPR/Cas9 is also limited to 
targets that are flanked by a PAM sequence that will trigger its targeting mechanism [8]. 
On the opposite side of the spectrum, theoretically any DNA sequence that contains the 
required PAM sequence of NGG can be a target for the CRISPR/Cas9 system with 
various binding probabilities - even excerpts of DNA outside the target sequence [7]. As 
a result, off-target effects are known to occur with employment of the CRISPR/Cas9 
system [8]. Researchers have already made steady advances in improving accuracy 
through a number of methods, including a propitious double-nicking strategy that uses a 
Cas9 nickase mutant with paired gRNAs [8]. Due to these advancements and the 
development of a number of online tools, deep sequencing assays have reported in vivo 
off target cleavages mostly in noncoding region of host genomes, while whole exome 
sequencing has shown no off-target events in CRISPR/Cas9-modified human cells when 
targeting the C4BPB and CCR5 genes [7]. In addition, the knowledge gap surrounding 
the application of the CRISPR/Cas9 gene-editing system to animal zygotes and human 
cells, and its potential off-target cleavage and recombination, is being thoroughly 
investigated to explore opportunities to expand fidelity and specificity – materializing 
critical milestones on the path to in vivo clinical application [16]. 
 Complications also arise from the need to properly deliver the CRISPR/Cas9 
system, as simultaneously delivering both the gRNA and Cas9 components required for 
target site recognition and excision is more problematic than delivering each 
independently [7]. A number of approaches to deliver Cas9 and gRNA expression 
plasmids into mammalian cells have been achieved, including microinjection, 
electroporation, nucleofection, lipofectamine, and lentiviral vectors [7]. It thought that in 
11 
 
due time viral vectors may be the best method of delivery for the CRISPR/Cas9 system 
and associated gRNAs, as they have already been used to achieve mutagenesis ranging 
from 18% to 65% success in a diverse array of human somatic cells, both transformed 
and non-transformed [17]. However, the selection of the proper delivery system is 
contingent on the cells, tissues, and organisms that are being targeted, with safe delivery 
to multicellular organisms presenting a deadlock in the development of the technology, as 
it is currently understood [10]. 
Compared to other genome editing technologies, such as zinc-finger nucleases 
(ZFNs) and transcription activator-like effector nucleases (TALENs), CRISPR/Cas9 is 
far more easily customized, presents a cleaner cleavage pattern, and displays a superior 
editing efficiency [8]. Cas9 can be retargeted to different DNA sequences by merely 
purchasing a 20 nucleotide guide sequence oligonucleotide whereas ZFNs are generally 
onerous to customize and retargeting of TALENs requires the construction of two new 
TALEN genes [8]. The cleavage pattern of CRISPR/Cas9 is also superior to the 
nonspecific cleavage of ZFNs and TALENs because it makes a precise, blunt, cut 
between the 17th and 18th bases in a target sequence [8]. CRISPR/Cas9 also has the 
unique ability to edit a variety of cell types and organism due to the ease of targeting and 
the ability to target multiple genomic loci simultaneous by co-delivering multiple gRNAs 
[8]. In addition, the superior effectiveness of the CRISPR/Cas9 site-specific cleavage, in 
direct comparison to ZFNs and TALENs, has been confirmed in in vitro studies of 
genetic modifications in zebrafish embryos for the same genes - while also offering a 
simpler approach and access to sites of the genome that were previously inaccessible to 
other gene-editing methods [18]. Furthermore, using the CRISPR/Cas9 platform to 
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mediate sequence alterations is considerably cheaper than any other approach currently in 
use [18]. 
 If the challenges surrounding the CRISPR/Cas system are addressed, it’s likely its 
utility will be near unlimited. In a biological context, CRISPR spacers can be used to 
provide insight as to the origin and evolutionary paths of some strains that can further the 
ecological and epidemiological study of microbes [3]. Ironically, phages might also be 
able to acquire and use CRISPR/Cas systems in their own genomes to target the defense 
systems of their desired host [1].  CRISPR/Cas9-mediated genome editing has also 
accelerated generation of transgenic models and will continue to expand biological 
research to rapidly model the causal roles of specific genetic variations in disease [6]. 
CRISPR-based immunity has also sparked advances in industrial applications by using 
hypervariability for typing purposes, driving viral evolution, predicting and modulating 
viral resistance in domesticated microbes, and providing a basis for natural genetic 
tagging of strains [3]. CRISPR/Cas systems also present the opportunity to impede 
nucleic acid transfer that could preclude the propagation of undesirable genetic elements, 
such as antibiotic resistance, virulence traits, and genes that are toxic to human and other 
organisms [3]. The system could even be designed to inhibit intracellular dissemination 
of migrant genetic elements like insertion sequences and transposons that jeopardize the 
integrity of industrial strains used in the biotechnology, pharmaceutical, and bioproduct 
industries [3]. In addition, the ability of the CRISPR/Cas system to also target RNA 
sequences implies that the technology could also be used to affect the transcription of 
chromosomal elements [3]. As early as 2014, a modified CRISPR/Cas9 complex coined 
CRISPR inference (CRISPRi) has shown the ability to regulate gene transcription 
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through irreversible DNA modifications [10]. It is hoped that precise genome editing that 
can permanently cure diseases through disruption or correction of endogenous 
causational genes, or insertion of protective genes, is not far behind [10]. 
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Chapter 2: Applying CRISPR/Cas9 Gene Editing to Excise HIV-1 Quasispecies 
Introduction to HIV-1 
Since discovery in 1981, HIV-1 infection, and the associated clinical progression 
to the most severe form of the disease, the acquired immunodeficiency syndrome (AIDS), 
has emerged as one of the largest global epidemics [16]. As of 2014, it has been projected 
that roughly 39 million deaths worldwide can be attributed to infection by HIV, and 
approximately 35 million people are currently suffering from the disease [19]. As a 
result, the HIV-1 epidemic represents over an $18.9 billion dollar loss to the world’s 
economy, and has even been means for discrimination [20]. 
Although HIV/AIDS research has received enormous social and economic 
attention, the fact remains that there is no cure that will remove the viral genome from the 
affected cell populations that results in the eradication of the disease from patient 
populations entirely [21]. Treatments have evolved to mitigate symptoms by inhibiting 
viral replication and restoring immune system function, which include highly active 
antiretroviral therapy (HAART), but reemergence of the virus has been observed after 
treatment [22]. This is because HIV, as a retrovirus, infects a host by integrating its DNA 
into the genome of the infected cell and it is subsequently replicated along with cellular 
DNA  [23]. The proviral DNA has been shown to exist in infected reservoir cells serving 
as a source for virus propagation, and the eventual development of HIV-1 “quasispecies” 
when the latent genome is induced into productive viral gene expression. Based on the 
lack of gene expression within most cells of the reservoir these cells lack the production 
of viral protein that would drive a host immune response [22]. As such, these latently 
infected cells, most notably the pool of resting CD4
+
 memory T-cells, present an 
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enormous challenge in developing a cure for HIV based on currently available strategies  
[22]. 
One novel approach to the therapy centers on the usage of the CRISPR/Cas9 
gene-editing system for targeted excision. The system, already shown to have great utility 
in a diverse number of genetic engineering applications, is being deployed to remove 
proviral HIV-1 DNA from the host cell genome by targeting highly-conserved 5’ and 3’ 
long terminal repeats (LTRs) [24, 25]. Current methodology developed by our 
collaborators at the Temple University School of Medicine has demonstrated this use 
with the excision of a 9.7 kb fragment of proviral DNA, although further development of 
delivery vectors and gRNAs will be required  to allow for complete coverage and 
excision of all quasispecies present within an ex vivo clinical sample [25]. Due to the high 
mutability of HIV-1 there often exists quasispecies with 2-50 genetic variants [26], and a 
need to excise them all in order to effectively sterilize latent reservoirs from which the 
virus might otherwise reemerge. 
Although HIV-1 genomic variability represents a very unique and challenging 
hurdle that must be overcome in order to effectively apply the CRISPR/Cas9 system of 
gene editing to excise HIV-1 proviral DNA from host genomes, we have also identified a 
unique opportunity based on the organization of the HIV-1 genome that will ultimately 
increase excision efficacy. This opportunity lies in the selection of gRNA target sites that 
are within the HIV-1 LTR promoter. In addition to being vital to drive transcription of the 
HIV-1 genome, these 5’ and 3’ LTRs of HIV-1 exhibit high sequence conservation which 
will give each gRNA selected a larger likelihood of cleavage, both within patient 
quasispecies and between patients [27]. These sequences are also identical on both the 5’ 
16 
 
and 3’ prime ends of the HIV-1 genome, meaning the selection of a target within either 
will likely produce a cleavage site in both, increasing the efficiency of the excision 
process [27]. 
Identification of the Problem   
Since the emergence of the HIV/AIDS epidemic, countless efforts have been 
launched to cure HIV-1 infection. Current strategies, such as highly active antiretroviral 
therapy (HAART), have improved survival rates among AIDS patients but have proven 
insufficient to prevent the reemergence of the virus, due to the formation of viral 
reservoirs that can, under certain conditions, escape therapeutic and immunologic control 
[24]. As such, a “sterilizing cure” of HIV-1 exists only when the virus, in all existing 
quasispecies, has been excised from all host cell chromosomal locations present within 
every cell in every reservoir. Utilizing this strategy, Dr. Khalili and coworkers at Temple 
University have developed an HIV-1-specific gene editing strategy, based on the 
Cas9/CRISPR excision system, to identify and excise proviral DNA by using guide 
RNAs (gRNA) complementary to the HIV-1 genome. As a result, for this technology to 
be able to be considered as a potential therapeutic, there is a need to efficiently and 
timely identify gRNAs for excision of all HIV-1 quasispecies in a given patient.  To help 
meet this need, HIV-1 sequences obtained from the Drexel Medecine CNS AIDS and 
Eradication Research (CARES) Cohort and the application of the Illumina HiSeq NGS 
DNA sequencing have been integrated into a bioinformatic pipeline that has identified the 
optimal number and nucleotide composition of gRNAs required to remove all integrated 
quasispecies from the peripheral blood of a given HIV-1-infected patient. These gRNAs 
have been identified from LTR regions after deep sequencing of integrated HIV-1 
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proviral DNA from the peripheral blood mononuclear cell (PBMC) compartment. Due to 
the sheer amount of genomic data, the bioinformatic pipeline was developed to utilize 
SMRT sequencing strategies in order to elucidate these regions and facilitate the 
Cas9/gRNA excision strategy while minimizing the computational cost of the analysis. 
As a result, the bioinformatic pipeline that was designed and implemented shows the 
promise of excising the entire HIV-1 genome (in all quasispecies) from HIV-1 infected 
patient CD4
+
 memory T lymphocytes, pending the development of a suitable method of 
therapeutic delivery. 
Obtaining Next Generation Sequencing (NGS) Results of HIV-1 Proviral DNA 
 For both reliable and accurate analysis of proviral genomic sequences, the 
methods required to gather this information must be able to distinguish predominant 
sequences from a cloud of similar, but variable, quasispecies sequences. Although some 
quasispecies sequences may be present with greater frequency than others, it is 
imperative that excision can be optimized with all these HIV-1 variants considered, as 
even a single proviral genome has the ability to replicate and serve as a source for 
reemergence for the virus. Enter next generation deep sequencing, the parallel mass 
sequencing of genomic fragments, which is an extremely potent tool for bioinformatic 
analysis. However, as useful as the unprecedented data is, bioinformaticians still struggle 
with the sheer amount of data and the degree of complexity associated with de novo 
mapping of the sometimes hundreds of millions of short deep sequencing reads, along 
with the extensive read cleaning that is required after assembly. Analysis is further 
complicated by varying error profiles that change even between runs of the same 
technology, along with errors introduced by PCR and amplification procedures that are 
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required to provide NGS platforms with enough input DNA [28]. Fortunately, with the 
advent of newer, more powerful, sequencing technologies, a great number of software 
tools have also evolved to use the vast amounts of generated data for further insight and 
application that would otherwise be unobtainable. The difficulty lies within selecting the 
correct tools to adequately treat a data set, as the transformation of raw sequencing data 
often requires sophisticated computational analyses to form well-mapped, contiguous, 
reads. The task of selecting and personalizing these tools is onerous, and sometimes 
causes bottlenecking in bioinformatic pipelines that can paralyze analysis. 
Besides from being a cheaper progression of sequencing technologies, next 
generation sequencing (NGS) also provides the accessibility to genomic data that has 
seemingly endless utility in the field of bioinformatics. Deep sequencing technologies are 
often used in studies of genetic diversity and the understanding of intra-patient viral 
genomics has implications with respect to evolutionary dynamics of viruses that guide 
design of effective antiviral therapies, as well as vaccines [28]. In one instance, 
longitudinal whole genome sequencing was used to detect the emergence of low 
frequency escape variants during the course of HIV-1 infections that developed as an 
adaptation to immune responses from host CB8
+
 T-cells [29, 30]. Studying the genomic 
data derived from HIV-1-infected patient populations has also been used 
epidemiologically to dissect transmission events [29]. In the case of HCV, deep 
sequencing has been used to identify intra-host evolution during early infection and imply 
that transmission and infection causes a genetic bottleneck that only four or fewer virons 
can overcome [29]. Viral integration sites are also identified and isolated from viral deep 
sequencing data to determine the physical nature of the  integration site [31]. The role of 
19 
 
the V3 region of HIV-1 gp120 in cellular tropism in particular, distinguishing CCR5- or 
CXCR4-using viruses, has been approached by the appreciation of deep sequencing data 
[32]. Bacterial populations, too, are deep sequenced to elucidate events in bacterial 
evolution that lead to drug resistance, immune response escape mutations, and genes 
involved in bacterial virulence. Understanding these events, along with the 
characterization of transmission networks, provide tremendous promise for developing 
therapeutic responses against bacterial pathogens [29]. Deep sequencing technologies 
have also been used to measure gene expression levels, discover emerging viruses, and to 
metagenomically profile bacterial communities [29]. 
 To provide the data for these studies, and ours, there are a number of sequencing 
technologies that have been developed over the years. Chief among them are the (1) 
Sanger technologies, involving sequencing of clones or PCR products for predominant 
genotype determinations, (2) NGS 454 Pyrosequencing, and (3) Illumina technologies. 
Among all three techniques, even between NGS platforms, differences are observed in 
cost, read lengths, error patterns and rates, run time, and capacity. Sanger sequencing, 
though being phased out by the far cheaper and less labor intensive NGS methods, is 
characterized by relatively long reads of ~1000 bp [33]. It is performed by using a DNA 
primer, a DNA polymerase, and normal deoxynucleosidetriphosphates (dNTPs) to 
replicate a single-stranded DNA template and terminating the elongated replicant strands 
with di-deocynucleotidetriphosphates (ddNTPs). Specific base sequences are then 
inferred by separating and cataloguing replicant strands by length, using gel 
electrophoresis [34]. Sanger sequencing also observes the lowest error rate of the 
technologies, at 10
-5
 error per base [33]. Due to the long reads and low error rate of 
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sanger sequencing, but at higher costs and with more required work, it is now used 
primarily to verify the accuracy of NGS sequencing techniques. 454 Pyrosequencing, on 
the other hand, utilizes isolated DNA and replicates it on micro-droplet emulsion PCR. 
Beads are loaded into 1.6 million wells on a picotiter plate, where a single template may 
amplify a sequence several thousand times as it is washed with enzymes for 
pyrophosphate sequencing [28]. With 454 Pyrosequencing, insertions and deletions 
(indels) are the most commonly observed type of errors, with error rates increasing with 
read length and an average read length of ~600 bp [28]. Illumina also relies on its own 
novel technique of amplification. Initially, a single-stranded template is primed and 
extended before repeated cycles of annealing, extension, and denaturation, form 
approximately 200 million molecular clusters. Nucleotides are added for sequencing, 
each labeled with a different dye and a modification that will halt DNA synthesis after its 
integration to a replicant strand. Fluorescent dyes are then removed while a color imaging 
algorithm determines the nucleotide that was represented, determining the sequence of 
each strand [28]. Illumina reads are not as prone to indel errors as 454 Pyrosequencing, 
but do experience substitutions at a similar frequency as well as some artificial indels. 
Mismatching also increases with read length, with the average read length being ~300 bp 
[28]. Altogether, 454 Pyrosequencing produces longer reads with lower coverage, 
provides advantages when matching diversity at sites further than the read length, and the 
higher error rate per base of 0.596+-0.02% and 1.096+-0.01% for non-PCR and PCR 
samples [35]. Illumina sequencing provides higher coverage at a shorter read length, less 
noise, a lower cost per base sequenced, and a sequencing error rate of 0.17+-0.01% and 
0.38+-0.01% error per base for non-PCR and PCR samples [35]. Both 454/Roche and 
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Illumina NGS technologies have been applied to estimate viral diversity in HIV-1 
molecular clones to determine that Illumina reads, which are generated at higher 
coverage and can thus detect variants at lower frequencies, are generally insufficient to 
assemble full-length haplotypes - unlike that of 454/Roche reads [35]. 
With all sequencing technologies representing a sizeable investment of time and 
money, simulation methods have emerged to provide sequencing data for the tuning of 
analytical methods without a substantial commitment of resources. There are a number of 
robust and reliable simulators, among them being GenFrag, SAMtools, MetaSim, 
SimSeq, ART, and GemSIM. GenFrag is a set of tools that creates data sets using 
parameters that are systematically and independently varied to explore the range of 
sequencing data within a given project [36]. The Sequence Alignment/Map format and 
SAMtools are an alignment format for storing read mappings with reference sequencing 
that is supplemented by a number of utilities for post processing alignments such as 
indexing, variant calling, and alignment viewing  [37]. Similarly, MetaSim is a software 
that generates collections of synthetic reads derived from a database of genomes that can 
be present in user-specified levels [38]. SimSeq is a program that has been used to 
generate short reads but with a simulated error based on NGS error models [39]. ART 
provides a set of simulation tools that will create novel NGS sequencing data, also with 
technology-specific error read models, and the ability to customize read error model 
parameters along with quality profiles [40]. Finally, GemSIM has been shown to be 
capable of generating both single or paired-end reads for any sequencing technology, 
along with error models, and in many different generic formats. Fragment lengths and 
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quality score distributions can also be specified from one or more haplotype sets or 
genomes [41]. 
 Once sequencing data is obtained, real or synthetic, accurately mapping short 
reads to a genome must be done with great care in order to avoid bias. Many types of 
mapping software are unable to process increasing levels of genetic variation, resulting in 
data loss. Many types of software are limited by their handling of genome gaps, 
incorporation of quality scores, paired ends option, or simply with the average read 
length, as alignment of longer reads has put increased pressure on computational efficacy 
[29]. Currently, most software tools maintain a trade-off between depth, shorter read 
lengths in greater quantity, and breadth, fewer reads that are longer and have more 
certainty as to where they should be assembled. Balancing of these alignment parameters 
should be determined based on the unique data set, the design of the experiment, and the 
desired analysis in mind. Quality of alignment should also always be inspected via a 
visualization program [29].  A very common approach in these software packages is the 
use of a De Bruijn graph-based assembler that use suffix trees as data structures for 
detecting and correcting short read errors. Regardless of the approach, however, a direct 
relationship between the number of reads to be mapped and the distinction from the data 
and template sequence has been observed. Using an unsuitable template will introduce 
unnecessary bias and result in non-random data loss [42]. 
 After assembly, NGS reads must undergo thorough read cleaning to ensure 
quality of alignment of the data. This step brings a deep sequencing pipeline to fruition in 
that it identifies variants from aligned reads and provides matching certainty to an aligned 
sequence. A multitude of software tools exist to distinguish single nucleotide variants 
23 
 
(SNVs) in alignment reads, using either cut-off based filtering (k-mers) or varying 
statistical tests, often with weighted quality scores, to differentiate between errors and 
actual variants [29]. To correct indels, a high-quality alignment is required and it can be 
provided by a computed multiple sequence alignment (MSA) to distinguish approximate 
location of reads on a genome [28]. In some cases, distinguishable strand bias can be 
used to verify the validity of a variant [29]. Included in these tools, Quake is a program 
that uses a maximum likelihood approach that includes quality values and nucleotide 
specific miscall rates to detect and correct errors in sequencing reads [43]. Eulerian 
methods use the classical Eulerian path problem to distinguish solutions of large-scale 
sequencing reassemblies, without masking repeats and instead leveraging them to clean 
reads using trusted (highly covered) k-mer assembly. Low frequency k-mers are 
presumed errors and thus corrected [44]. SHREC is an algorithm that uses a generalized 
suffix tree data structure to identify erroneous reads in short-read data, with exceptional 
sensitivity and specificity of over 99% [45]. SOAP2 is also a powerful tool for short read 
alignment, as a program that has been shown to focus primarily on maximizing 
computational efficacy by reducing computer memory usage to produce unprecedented 
alignment speed [46]. Lastly, VarScan is an open source software that is compatible with 
many short read aligners and can detect SNPs and indels with high sensitivity and 
specificity [47].  
 After well-mapped sequences have been achieved, sequencing data can be used to 
perform haplotype reconstruction. This involves the cataloging of individual reads into 
source haplotypes and assembling longer segments of genome from the shorter, 
overlapping, read lengths [29].  The accuracy of which decreases significantly if 
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amplification bias or chimera errors are in read lengths [29]. Chimeras, resulting from 
recombination during library preparation, can be minimized by selecting amplification 
protocols with the least cycle numbers or strict amplification conditions [29]. There are 
two types of haplotype reconstruction, local and global, and they are differentiated in that 
local haplotype inference refers to the analyzing of windows in the MSA that reads cover 
entirely. Global haplotyping is the piecing together of local fragments into a number of 
haplotype sequences that span the entirety of a genomic region, and is also referred to as 
quasispecies assembly. Global reconstruction is primarily done using three techniques: 
the graph-based minimum set of paths problem, probabilistic clustering models, and de 
novo assembly methods without comparison to a reference sequence [28]. Clustering 
works particularly well if error rates are low relative to a population diversity and with 
greater coverage; these conditions also justify the assumption that reads from the same 
haplotype are more similar to one another than that of other haplotypes [28]. In the case 
of mixed samples, error correction and haplotype reconstruction are intimately 
interlinked and usually addressed together due to the different spatial scales of haplotype 
inference that correlate to the length of the target genomic region [28]. In general, global 
haplotype reconstruction is easier with the longer contiguous reads from the 454/Roche 
[35]. However, both sensitivity and specificity are higher for local haplotype 
reconstruction with shorter Illumina reads [35]. Existing programs for haplotype 
reconstruction deploy a number of different technologies to offer different approaches 
with their own unique attributes. ShoRAH uses multiple read alignments to construct 
local haplotypes by adjusting errors in sequencing that overestimate predicted diversity 
[43]. V-phaser recalibrates base quality scores once accounting for phasing and quality 
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scores of variants within a read [29]. BIOA assembly algorithms reconstruct viral 
quasispecies also, and the methods have been validated on simulated, error-free, HVC 
and real HBV reads [48]. Specifically designed for long reads (>100 bp) is QuRe, another 
software for viral quasispecies reconstruction that uses a heuristic algorithm [49]. 
QColors is an algorithm designed specifically for low haplotype diversity and low read 
coverage that solves for optimal quasispecies subsequences via vertex coloring of conflict 
graphs [50]. 
 With the great number of options and tools available in all stages of mapping 
construction, there remains a great deal of uncertainty as to what will have the best 
possible yield for analysis. Furthermore, holistic evaluations of all stages of read 
mapping, cleaning, and haplotype reconstruction, have not been thoroughly explored. 
However, the critical nature of applying an assortment of tools and filters that reduce 
error rates and address variant detection has been made obvious by a 290-fold cumulative 
error reduction achieved by Reumers, et al. when working with the sequencing data of 
monozygotic twins [51]. It is imperative to address the ambiguity of tool selection and 
calibration such that a tailored approach can be designed to optimize a bioinformatic 
pipelines for NGS sequencing data and its anticipated yield. This will ensure that there is 
a high enough confidence level in the input data that will still lend integrity to the 
analysis performed. 
Current HIV-1 Applications of the CRISPR/Cas9 System 
In “Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus,” 
Hirotaka Ebina, et al. describe the present state of HIV-1 treatment by highly active 
antiretroviral therapy and its inability to prevent reemergence from latent reservoirs [24]. 
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The treatment, a mixture of compounds that suppresses the HIV-1 viral life cycle, greatly 
reduces viral replication in cells and plasma viremia that support HIV-1 infection [52]. 
However, it does not suppress low-level viral genome expression and proliferation in 
tissues and cannot fully eradicate HIV-1 from latently infected reservoir cells that include 
brain macrophages, microglia, astrocytes, gut-associated lymphoid cells, and more [52]. 
Even during HAART, HIV-1 patients have roughly ~10
6
 infected cells at any given time, 
cells that will continue to afflict the patient by contributing to heart and renal diseases, 
osteopenia, and neurological disorders [52]. As a result, it is widely accepted that 
HAART, and related therapies, are insufficient to truly cure a patient of HIV-1 infection 
and that future attempts at a cure will likely include interception and removal of the virus 
at a nuclear level in all cells. Hirotaka Ebina, et al. go further to demonstrate the potential 
beginnings of the first nuclear cure for HIV-1 in the CRISPR/Cas9 system, taking 
advantage of the system’s unique gene-editing ability to excise the HIV-1 genome and 
prevent expression in T cells. Confirmed by sequence analysis, it was shown that the 
CRISPR/Cas9 system effectively cleaved targeted LTR sites and removed internal viral 
genes from infected cell chromosomes while ignoring human genes. Subsequently, they 
observed a substantial decrease in LTR-driven expression after stimulating their cell lines 
[24]. In addition, Wenhui Hu, et al., have applied the same approach to highly specific 
targets within the HIV-1 LTR U3 region, inactivating viral gene expression and 
replication in latently infected microglial, promonocytic, and T cells. This was done 
without causing genotoxicity or off-target editing, and also completely excised a 9,709-
bp strand of integrated proviral DNA that spanned from the host cells’ 5’ to 3’ LTRs. The 
work, as described in “RNA-directed gene editing specifically eradicates latent and 
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prevents new HIV-1 infection,” provides a powerful implication that the gRNA/Cas9 
system can be further engineered to completely excise HIV-1 proviral DNA and prove to 
be a curative measure against HIV infection [52]. 
In order for that to become true, the excision abilities of the CRISPR/Cas9 system 
must be enabled to remove all quasispecies in a patient. These quasispecies rapidly 
evolve and display extensive sequence variation to combat host-specific selection, 
exhibiting a Shannon entropy of 0.75 per amino acid, as confirmed by a population-based 
inter-patient study of 686 HIV-1 patients in the HOMER cohort in British Columbia, 
Canada [15]. The same study went further to estimate within-host sequence coevolution 
lineages among patients from 2 to 9 lineages with a mean of 4.6 lineages, although it was 
specified that this is a conservative estimate due to the method of phylogeny 
reconstruction [15]. Similar studies have confirmed the high level of genetic variation of 
HIV-1 in comparison to other retroviruses and reiterated the need to determine these 
quasispecies for effective target-based excision using the CRISPR/Cas9 system [53]. 
Louis Mansky and Howard Temin at the University of Wisconsin were able to identify a 
forward mutation rate for HIV-1 at 3.4 x 10
-5
 mutations per basepair per replication cycle 
in an in vivo assay, also determining that the in vivo mutation rates for HIV could be three 
to seven times higher than two other retroviruses, spleen necrosis virus and bovine 
leukemia virus, respectively [53]. Due to this thoroughly documented variability, gRNAs 
must be identified that can properly equip the CRISPR/Cas9 gene-editing complex to 
target and excise 2-50 genetic variants [26]. Without such coverage, latently infected 
reservoir cells will serve as a source for reemergence of the virus, even after excision of 
some proviral DNA [22]. In addition, the mutation rate of the HIV-1 genome requires 
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that the viral variants be excised before further mutation occurs that would render a 
specified gRNA ineffective [23, 26]. We postulated that an algorithm could be developed 
to process patient genome sequences and identify the gRNAs needed for this developing 
technology to completely excise all known HIV-1 proviruses after antiretroviral therapy 
has narrowed the spectrum of quasispecies to a manageable number, but before mutation 
makes each species untargetable. 
Methods and Materials 
Genomic data obtained for the implementation and tuning of the bioinformatic 
platform was obtained from PCR amplification and sequential Illumina HiSeq 
sequencing, using a 2
nd
 generation mid-output plate. The reads were then mapped to the 
HXB2 reference genome using the BWA mem algorithm, with any duplicates being 
removed by the samblaster tool. Aligned reads were then piled with samtools, yielding an 
operable dataset for analysis. Because the computational power required to compile and 
execute the platform in its entirety was significant, a 32-core, 3.8 GHz Dell Precision 
Supercomputer with 128 GB of RAM and 4 TB of hard-drive storage was utilized in 
order to process our analysis as quickly as possible. The computer, located within the 
Bioinformatics Suite within the Center for Molecular Virology and Translational 
Neuroscience in the Institute for Molecular Medicine and Infectious Disease and the 
Department of Microbiology and Immunology at the Drexel University College of 
Medicine, ran Ubuntu Linux and had an expansive assortment of tools and statistical 
packages already installed for sequence analysis. The predominant environment for 
development was PyCharm, which provided code analysis, a graphical debugger, an 
integrated unit tester, VCS/DVCS integration, and web development accessibility 
29 
 
throughout the implementation process. Our primary development environment was 
aided by the use of iPython Notebook as well, as an intermediary that allowed us to 
troubleshoot excerpts of code before integration to the body of the bioinformatic pipeline. 
The environment was cross-platform, and had the ability to compile both Java and 
Python, although our algorithm was developed exclusively in Python. 
Technical Considerations 
The technical level of the project was classified as highly advanced. First, a 
fundamental understanding of the techniques of molecular biology was required to 
appreciate the purpose and objectives of the algorithm platform in the context of the 
RNA-guided Cas9/gRNA gene cleavage system. In addition, advanced programming 
experience was required to integrate arms of the bioinformatic platform to seamlessly 
achieve the design objectives and implement the necessary data structures and 
subroutines for analysis. This included the ability to process genomic data from 
haplotype reconstruction following patient sequencing. The processing of the 
bioinformatic analysis required usage of a Dell Precision Supercomputer in order to 
minimize run time. 
Technical Design 
 At the onset of the technical design of the pipeline, we first had to develop a deep 
understanding of what data was available to us in order to elucidate the most targetable 
regions of the HIV-1 genome for optimal excision. This was no simple task, as the nature 
of NGS technologies to provide extremely parallel, cost efficient, sequencing of genomic 
fragments in hundreds of thousands to hundreds of millions of short reads comes at a 
very real risk of error in predicting each basepair [29]. This risk stems from the imperfect 
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acquisition of read depth from NGS technologies, where variants with extremely small 
population frequencies (under 1%) are still of interest to our analysis that includes 
determining, even if infrequent, are all viral quasispecies that exist in a given patient [29]. 
Without determining all of viral quasispecies for excision it is extremely likely that HIV-
1 virus will reemerge, as leaving just one proviral genome uncleaved will lead to 
propagation of the integrated proviral DNA the next time the latent genome is activated 
into a productive round of viral replication. With that having been stated, errors that 
might contaminate the reads can take place in many of the steps that are required to 
obtain useful data for analysis, including during DNA or RNA extraction, PCR 
amplification of target regions, library preparation and sequencing, read quality control 
and filtering, de novo assembly, consensus calling, alignment, variant calling, and 
haplotype reconstruction [29]. 
In brief, the PCR procedure amplified the 9.7 kb genome in 4 overlapping 3 kb 
fragments. These were performed separately using High-Fidelity polymerase and a 
minimum number (20) of amplification cycles. Amplicons were combined in equimolar 
ratios and prepared for sequencing on the Illumina HiSeq using a 2
nd
 generation mid-
output plate. The sequencing procedure returned an average of 7 million paired end reads 
of 150 nucleotides separated by a 200 basepair spacer. Reads were then aligned to the 
HXB2 genome using the BWA mem algorithm, and duplicate reads were removed using 
the samblaster tool. Samtools was used to ‘pile’ the aligned reads utilizing the default 
parameters. Ultimately this sequencing data would manifest as a matrix in which the rows 
corresponded to positions in the HIV-1 genome (1-9717) and the columns contained the 
31 
 
number of times each nucleotide was observed at that position. This is the data that would 
be used as an input to all future algorithms presented. 
Our ability to detect low frequency haplotypes for excision was a function of the 
depth of sequence coverage, the error rate of the PCR amplification, and the error rate of 
the sequencer. In order to quantify these parameters a calibration experiment was 
performed in which the initial concentrations of known sequences were tested. Four 
molecular clones containing HIV sequence were serially diluted in relative concentrations 
ranging from 1:1:1:1 to 1:1:1:50,000, PCR amplified, and sequenced using a technique 
identical to what will be used on patient samples. The number of reads that mapped to 
each position in this calibration experiment is shown in Figure 2. 
 
 
 
 
Figure 2: An example of measurable coverage of mapped reads of the HIV-1 
genome, by position. The x axis depicts the position in the reference HXB2 strain 
genome, with the y axis measuring the reads mapped to each position. In this example, 
the average position was covered by more than 30,000 reads and as such it was expected 
to detect variants up to 1 in 30,000. Our level of detection for minor frequency variants 
yielded from NGS sequencing is 1:1,000 over the LTR region of interest.  
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After ensuring confidence in the sequences used for analysis, we could then set 
out to determine exactly what gRNAs would give the most promise of proviral DNA 
excision in each quasispecies with the approach previously descrived by Dr. Khalili and 
colleagues. In order to circumvent the complexities, and possible error retention, of 
haplotype reconstruction for each viral quasispecies, we used sequencing data from 
known HIV-1-laboratory strains in a similar format such that we could still process 
sequencing data by implementing a bioinformatic pipeline that would (1) find all possible 
excision sites marked by the PAM sequence, (2) determine the resultant gRNA sequence 
from the preceding 20 basepairs, (3) determine the cutting efficacy, or binding affinities, 
for each gRNA applied to its own HIV-1 strain and others and, finally, (4) determine the 
number of gRNAs that would need to be delivered to each patient, or spectrum of HIV-1 
quasispecies, in order to obtain 99.99% excision.  
 The sequencing data of the HIV-1 laboratory strains that was used to implement 
the bioinformatic pipeline closely resembles Figure 3.  The data was obtained in .tsv 
(tabulated tab-separated values) format, and was imported to our Python environment for 
processing. NGS technologies would provide for very similar data in terms of content, as 
the objective of the sequencing and haplotype reconstruction is to provide the most 
accurate sequences of HIV-1 strains, which is what is shown below. 
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Figure 3: An example of obtaining sequencing data that was used for analysis. The 
data pictured includes all the fields leveraged for processing as presented from the NGS 
platform. The difficulty of determining certainty of nucleotide sequences can be observed 
in the sometimes differing reference nucleotide as compared to the number of times that 
nucleotide that was physically measured in the well, “NumReads”. 
 
 
 
 Useful attributes of the HIV-1 laboratory strain sequencing data included the 
position (“Pos” column), or where in the viral genome each nucleotide was observed, the 
columns corresponding to each base and how frequently it was measured (the 
“A”,”C”,”G”, and “T” columns), the total number of reads that were collected for each 
position (“NumReads” column), the well that was being sequenced - which corresponded 
to the known laboratory strains we had placed in each (“Well” column), and the reference 
sequence of the known laboratory strain (the “Ref” column). In the case that the 
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measured nucleotide did not agree with the reference nucleotide in the same record, a 
“predominant basepair” was determined by calculating the most frequently observed 
nucleotide, which was captured from the “A”,”C”,”G”, and “T” columns. This 
established the most likely sequence of the HIV-1 strain that was in each well. The 
sequences were then processed by the remaining key elements of the pipeline as shown in 
Figure 4. 
 
 
 
 
Figure 4: The key elements of the bioinformatic pipeline that would yield the 
optimal gRNAs for excision. Each box above represents a primary building block but 
likely includes one to many functions and sub-functions that were designed to capture the 
functionality specified. The pipeline, in its simplest chronological form, is communicated 
with this figure. 
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After the sequences of each HIV-1 strain were determined, the first objective was 
to determine what sites in the viral genome were possible targets for gRNA excision 
based on the requirement of the PAM sequence, NGG (any nucleotide-guanine-guanine). 
A function, is_pam, was constructed to search through viral sequences to find these sites. 
The viral genome was analyzed in full with the application of the function, and the 
resultant gRNAs available to us for selection were determined by simply capturing the 
preceding 20 basepairs, resulting in a variable number of 23 bp gRNA sequences for each 
quasispecies. This was performed using the gRNA_seq function, which was implemented 
to return the 23-mer nucleotide sequence that was yielded from the position of a PAM 
sequence. Once all possible gRNAs were identified, they could then be evaluated for 
their numerical binding affinities both in their own patient quasispecies and in others with 
differing genomic sequencing composition, representing another patient’s viral 
quasispecies. In order to do so, each gRNA had to be given a quantitative measure of 
exactly how likely cleavage would be at a specified target site for comparative analysis. 
This was performed using a complex scoring algorithm that was derived from an 
investigation of Hsu, et al.’s research into the targeting specificity of gRNA-guided 
CRISPR/Cas9 system. Determined by over 450 gRNA targets where every possible 
single-nucleotide substitution in the gRNA was scored for targeting the EMXI locus in 
human cells, Hsu, et al. assigned each of the 23 basepairs in the gRNA 23-mer a 
numerical binding penalty if the target sequence was not an exact match to the gRNA 
guiding CRISPR/Cas9 cleavage [9]. The algorithm calculates the magnitude of a binding 
affinity with a nucleotide-by-nucleotide evaluation of gRNA to target homology, tallying 
binding penalties that might occur. Mismatches from the gRNA selected decreased total 
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binding affinity scores for a target based on number of occurrences, their positions, and 
their distribution [9]. Excision power was also weighted by the number of times a gRNA 
could cleave in the target sequence in order to minimize the chance of NHEJ correctly 
repairing viral genomic fragments, as increasing the number of cleavage sites increased 
the possible number of genome recombinations. The function apply_scoring used this 
scoring algorithm to apply a gRNA to a target position, and calculated a binding affinity. 
The Optimal PAMS set of functions and sub-functions then determined the user-specified 
number of gRNAs that exhibited the best likelihood of excision as determined by the 
largest binding affinity scores, and determined the percentage probability that it would 
cut a target sequence based on a binding affinity threshold that needed to be reached to 
assume target cleavage. We could then combine target excision probabilities with the 
calculation of a logical or probability for any number of gRNAs until reaching the desired 
percent excision probability of 99.99%. 
Implementation Task Schedule 
 The implementation of the design project took almost the entirety of the 2014-
2015 academic year, totaling at approximately nine months. Time was allotted to the 
primary tasks of completing preliminary research, simulating patient sequencing data for 
pipeline development, pipeline development and tuning, securing true patient sequencing 
data for analysis, verification of the design project, and finally processing of true patient 
sequences using the finalized bioinformatic pipeline. The maturation of these tasks can be 
seen in Gantt chart form in Figure 5. The design project began with preliminary research 
that began after August 1st, 2014 - the date of the design project petition submission. 
After delving deeper into the problems around constructing a true cleansing cure and 
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understanding where opportunities lay, sequencing data was obtained from HIV-1 
laboratory strains with which to develop the bioinformatic pipeline. Coding began as 
early as mid-September and proved to be the largest allotment of time for the project. As 
the functions and sub-functions that were required for data processing, locating PAM 
sequences, determining gRNAs, scoring of gRNAs, and calculating cut probabilities, 
were implemented, sequencing of patient genomes was being performed concurrently 
within the Centers for Molecular Virology and Translational Neuroscience and Genome 
Sciences in the Institute for Molecular Medicine and Infectious Disease and the 
Department of Microbiology and Immunology at the Drexel University College of 
Medicine. The true patient sequencing data was obtained just as the pipeline was 
finalized in mid-March, and left approximately six weeks for processing and verification 
of design effectiveness. The design project saw fruition within the petition’s proposed 
task schedule and estimated time allocations. 
 
 
 
 
Figure 5: The implementation task schedule Gantt chart showing the time 
attributed to each task in the technical design project. Although this schedule does not 
break out execution at an atomic level, all the major milestones were captured. There 
were parts of the task schedule implemented in tandem, but the majority of the project 
flow was sequential, based on the iterative design proposed from the project’s  
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Figure 5 (continued): conception. The figure captures, at a high level, the tasks required 
to bring the design project to fruition. 
 
 
 
Alternative Solutions 
 We have proposed in the technical design of this project the methodology that we 
believe to have the most viability to evolve into a sterilizing cure. This includes the 
determination of all HIV-1 quasispecies in a patient using NGS technology and using the 
bioinformatic pipeline designed in this journal to determine the most effectual gRNAs for 
cleavage personalized to each patient’s quasispecies. However, opportunities to 
differentiate in approach do exist beyond the methods we have described here. This 
includes the utilization of Sanger sequencing as opposed to NGS technologies and the 
combing of HIV-1 strain sequencing databases to attempt to identify a set of gRNAs that 
may be effective enough to universally excise proviral DNA from patients. There are 
distinct advantages and disadvantages to each of these approaches. 
 Sanger sequencing, while providing the longest consecutive reads and the lowest 
error rate of the sequencing technologies mentioned in this paper, is much more 
expensive and labor intensive than its counterparts. While this may provide for a higher 
degree of confidence in the data being processed for ideal gRNAs, the time required to 
obtain useable data might be too long to customize a cure for a patient before their HIV-1 
quasispecies evolve and the gRNAs become obsolete, as our results suggest that the peak 
delivery window should fall within 6-9 months but sooner, if possible (Figure 8, Figure 
9). Similarly, although it may be cheaper and faster to try to discern a universal set of 
gRNAs from the wealth of HIV-1 virus sequence databases that exist, it is likely that they 
will not properly excise all quasispecies from every patient. If that is the case, the 
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uncleaved HIV-1 proviruses will continue to be a source of viral activation and 
replication that will potentially lead to reamplification of the viral quasispecies. The 
observed variation of the virus has been noted, and it appears an unrealistic task to be 
able to adequately identify a number of gRNAs that can excise all proviruses - unless a 
delivery technique is discovered that can administer a greater quantity of gRNAs to a 
patient in one treatment. The feasibility of that approach, however, would still be very 
doubtful as suggested by Figure 8, Figure 9 and Figure 11 of our results. All three 
figures clearly show the comparison of inter-patient vs intra-patient gRNA determination 
and delivery, with gRNAs being applied across patient quasispecies being 
overwhelmingly less effective at excision, by orders of magnitude. In addition, that 
option would dramatically increase the probability of off-target effects, possibly making 
the treatment difficult to administer in the absence of off-target effects and toxicities. 
Verification of Design Effectiveness 
 Throughout the design project, several checkpoints were determined that could 
confirm both effectiveness and validity through development. To ensure that the pipeline 
was implemented correctly from the beginning, true patient sequencing data was obtained 
from investigators working in the Bioinformatics Suite within the Center for Molecular 
Virology and Translational Neuroscience in the Institute for Molecular Medicine and 
Infectious Disease and the Department of Microbiology and Immunology at the Drexel 
University College of Medicine to confirm the format and results of the simulated data. 
The patient sequencing data was also checked for reliability by determining exactly how 
many wells provided useable HIV sequence reads and how deep the obtained coverage 
was. Furthermore, the pipeline was able to consistently use this novel data to find and 
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score PAM sequences such that gRNAs could be graded accurately for comparison. 
These gRNAs, along with their nucleotide sequences and occurrences in the viral 
genome, could be verified with a simple function that was designed to query the patient 
data for confirmation of their existence. In addition to verifying the bioinformatic 
pipeline’s inputs and internal processing, we strived to determine exactly how effective 
the identified optimal gRNAs were when applied to other quasispecies. This was 
performed with multiple scorings against different strains, or quasispecies. An example 
of the gRNA applications can be seen in Figure 8 and Figure 9 in the subsequent Results 
and Discussion section. 
Results and Discussion 
After using the pipeline to process preliminary data and two sets of true patient 
sequencing data we observed reassuringly consistent results. From 22 HIV-1 patients we 
gathered adequate coverage for a total of 26 visits (for chronological comparison), 
yielding 26 total patient samples. Due to challenges with obtaining NGS sequencing from 
patient samples, only an average depth of 1,000X was obtained. Despite this technical 
difficulty, gRNA design was still performed with the added caveat. The bioinformatic 
pipeline described above was run on these samples to generate a set of potential gRNAs. 
For all patients at least 2 gRNAs were detected with at least a 25% cleavage rate, as seen 
in Figure 6.  
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Figure 6: The number of sequenced patients yielding gRNAs with cut coverage of 
over 25%. This histogram describes the number of patients with for which our algorithm 
can find a particular number of gRNAs with cut efficiencies over 25%. It can be seen that 
most patients fell within the 10-20 range, which is no small number as gRNAs can be 
delivered together to increase total cut coverage. 
 
 
 
Additionally, the exact location of these gRNAs in the HIV-1 HXB2 reference 
strain’s LTR promotor region (which provides for two cleavage sites, or double gRNA 
excision coverage) was determined as shown in Figure 7. The exact coverage provided 
by the sequencing of each position in the genome has also been specified in Figure 7. 
Although this was expected due to the high conservation of the 5’ and 3’ LTR regions, 
the Los Alamos HIV Sequence Database reference sequence for the HXB2 strain 
confirmed that many of these target areas were located in the sequences for TCF-1 alpha, 
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NK-kappa B II, NK-kappa B I, SPF1-III, SP1-II, and SP1-I, all human transcription 
factors. Human transcription factors fall within the human genome, suggesting that there 
would be off-target excision effects if these sequences are blindly selected for targeting 
(discussed in greater detail in Chapter 3). 
 
 
 
 
Figure 7: A plot of the HIV-1 reference sequence, its sequencing coverage, and the 
number of gRNAs with over 25% coverage that hit at each sequence position. This 
plot captures the sequenced viral quasispecies’ LTR region (positions 9086 to 9719 of the 
viral genome) as embodied by the HXB2 reference strain. Additionally, the first y axis 
shows the number of gRNAs that were gathered from these sequences and where they 
were located in the LTR region. The coverage depth (gray shading) is the number of 
reads that confirmed each positional read, establishing confidence in the determined 
gRNAs. This figure visualizes how many useable gRNAs were gathered from patient 
sequencing data and where in the HIV-1 LTR region they can cut, with the accuracy of 
these correlating to the coverage depth at each genome position. 
 
 
 
The gRNAs that were determined from each sequence can be observed in Figure 
8. Not only does this figure show how well a specific gRNA will cut on the source 
quasispecies genome (x axis), but it also provides a comparative analysis with respect to 
43 
 
excision likelihood on other quasispecies, as ordered by the y axis. The applications of 
gRNAs in different chronological time points (blue markers) of the same patient are used 
to determine the effectiveness of a particular approximately 6-9 months later. This aids in 
determining the longest possible period of time that we would have to sequence the 
patient and administer the CRISPR/Cas9 gRNA guided gene-editing systems before viral 
mutations make the personalized cure defunct. 
 
 
 
 
Figure 8: A two dimensional histogram offering source target comparisons of cut 
efficiency. Each hexagonal marker on this plot communicates cut efficiency of a number 
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Figure 8 (continued): of gRNAs (champagne shading) relative to both their source 
patient’s quasispecies genome (x axis) and a target patient’s viral quasispecies (y axis). 
The diagonal across the plot represents a 1:1 ratio of source to target cut efficiency. It can 
be seen here, and in Figure 9, that the overwhelming majority of gRNAs applied (black 
hexagonal markers) to differing viral quasispecies have very low cut coverage. However, 
as captured by the blue markers, gRNAs gathered from the same patient, and applied 1-2 
visits (6-9 months) later still had promising target cut coverage. 
 
 
 
 The information captured in Figure 8 is examined from another viewpoint in 
Figure 9. To this end, each pairwise comparison was categorized by target to source 
effectiveness, the blue columns still representing gRNA applications between the same 
patient’s visits whereas the champagne bars indicate a comparison between patients. It 
becomes apparent that the likelihood of successfully applying a complete excision across 
patients, that is selecting gRNAs from one patient’s quasispecies and applying them to 
another patient’s quasispecies, is very small. However, we can also see that roughly 40% 
of patient-specific gRNAs still achieve relatively effective proviral excision with no 
efforts being made to reduce the viral quasispecies in that patient between visits. This 
confirms that there is a timeline of delivery but that it is possible to administer patient-
specific complete excision after a significant time lapse, in spite of mutagenesis. 
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Figure 9: Target to source cut ratios by number of gRNA pairwise comparisons.  In 
this histogram, the total number of gRNA comparisons is captured by percentage (y axis) 
that fall within a range of target to source ratios (x axis). The target to source ratios are in 
negative log form, with the bars closer to the origin measuring a lower target cut 
coverage as compared to the source genome cut coverage. One can infer from this 
histogram that the majority of gRNAs applied to differing quasispecies yield small cut 
coverages, whereas application to the same quasispecies 6-9 months later is still feasible 
in roughly 40% of applications. 
 
 
 
The last of our primary objectives to be investigated and confirmed by the design 
project was the conjecture that it was possible to determine the number of gRNAs that 
could be reasonably delivered in a single vector and achieve a projected 99.99% excision 
likelihood of a viral quasispecies. This is confirmed by both Figure 10 and Figure 11. 
Figure 10 directly shows some of the more effective gRNAs being applied to patients 
sequentially, achieving greater cleavage coverage until .9999 probability is obtained. This 
probability was calculated using a cumulative-or function: p(A | B | C …) = p(~A | ~B | 
~C | …). The assumption that gRNAs were randomly associated with each viral 
haplotype was at the foundation of the calculated fraction of the observed quasispecies 
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that would be cleaved. gRNAs were then sorted in descending order by their cleavage 
fraction and the cumulative likelihood of excision was calculated. It was observed that of 
the samples examined the number of gRNAs required for complete excision was between 
4 and 10, depicted in Figure 10 below. 
 
 
 
 
Figure 10: The number gRNAs required to cleave the observed viral quasispecies to 
below the level of detection. Each line represents the application of N gRNAs to versus 
the fraction of the quasispecies that will be missed given that package. Where the lines 
intersect the x-axis provided an estimate of the number of gRNAs required to cleave the 
observed quasispecies. The plot shows that roughly 4-10 applied gRNAs can reduce the 
number of all uncleaved LTR quasispecies to undetectable levels. 
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Additionally, Figure 10 shows the number of viral quasispecies that remains 
uncleaved as an increasing number of gRNAs is applied, until the predicted surviving 
quasispecies count is approaching 0. A similar approach is shown across patients in 
Figure 11, showing the far greater number of delivered gRNAs that would be required to 
achieve the same cut efficiency. These results serve as a powerful implication that if 
sequencing is done rapidly, and gRNAs are selected specific only to a given patient’s 
quasispecies, that there is very real chance of thorough proviral excision pending proper 
delivery. For emerging technologies, this has been a very reassuring conclusion for the 
possibility of one day becoming a complete cure provided all HIV-1-infected cells can be 
targeting in all reservoirs. 
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Figure 11 (continued): The number of uncleaved LTR quasispecies as a function of 
gRNAs applied, across patients and chronologically. This figure shows the number of 
gRNAs needed to cleave different viral quasispecies from which optimal gRNAs were 
determined. It can be seen that, unlike Figure 10, the gRNAs required to cleave to our 
specified level of detection are substantially larger than the intra-patient determined 4-10 
gRNAs. This is determined by comparing gRNAs designed for patient A0223 at visit R03 
and applying them to all other patients (red lines). A chronological comparison is also 
offered by the blue dashed line, applying the gRNAs designed for patient A0223 at visit 
R03 to visit R04. You can see that for most "cross sectional" patients you never reach full 
coverage yet for the longitudinal sample you are nearly equally effective. 
 
 
 
Conclusions 
The design and implementation of our bioinformatic pipeline was successfully 
able to substantiate all the specific aims we set forth in our design objectives: (1) find all 
possible excision sites marked by the PAM sequences, (2) determine the resultant gRNA 
sequences from the preceding 20 bps, (3) determine the cutting efficacies, or binding 
affinities, for each gRNA applied to its own HIV-1 strain and others and, finally, (4) 
determine the number of gRNAs that needed to be delivered to each patient, or strain of 
HIV-1, in order to obtain 99.99% excision. In doing so, we have investigated critical 
questions of feasibility surrounding the application of the CRISPR/Cas9 gene-editing 
system to the integrated HIV-1 provirus for excision. We have determined that viral 
quasispecies of a patient can be determined and sequenced, via NGS sequencing 
techniques, and with confidence. From this data, we were able to accurately, and 
consistently, find targetable sequences in the viral genome’s LTR for the CRISPR/Cas9 
system, determine the exact sequences of these gRNA targets, and grade their cut 
probabilities. From that information, we have repeatedly been able to prove that some 
viral quasispecies can be excised with a 99.99% efficiency. Addressing these key 
milestones required to apply the CRISPR/Cas9 system to excise HIV-1 has materialized 
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serious evidence that the expansion of these technologies could, in fact, provide the basis 
for a sterilizing HIV-1 cure. 
Although significant progress has been made with respect to development of 
HIV-1 excision technology within the context of the inherent problem of viral 
quasispecies, a number of questions still remain unanswered. For example, what 
measures can be taken to reduce the number of viral quasispecies in a patient? 
Ultimately, this would narrow down the quasispecies needed to excise for a complete 
cure, dramatically increasing the effectiveness of the potential therapy. Currently 
available cART strategies have made it abundantly clearly that prolonged treatment (3-5 
years) can narrow the spectrum of quasispecies present in many patients to facilitate the 
identification of an effective package of gRNAs to guide an effective HIV-1 excision 
protocol. The available sequencing data in the CARES Cohort have also indicated that 
longer treatments do not appear to continue to narrow the spectrum quasispecies.  In this 
regard, the results appear to indicate that there appears to be a therapy refractile period 
during the course of HIV-1 infection that can be easily detected in the peripheral blood 
compartment even when assessing the predominant LTR genotype for prolonged periods 
of time. Additionally, although we have shown that gRNA guided CRISPR/Cas9 cut 
coverage can achieve 99.99% in some quasispecies, we have also determined that the 
effectiveness dramatically decreases when applying a gRNAs designed for one patient 
against another (Figure 8, Figure 9). Longitudinal sequencing data shows that 6-9 
months in our study suggested only 40% of cut coverage is preserved (Figure 8, Figure 
9). This raises the question of whether or not this is adequate time to acquire patient 
samples, sequence them, determine the needed gRNAs, build them, and delivery a 
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therapeutic within a timeframe that still captures a substantial cut coverage from the 
gRNAs originally determined. The methods described here also have been designed, 
implemented, and confirmed only computationally and serve as a predictive compass and 
projection for the excision process.  
The analysis could be extended with additional laboratory work, determining 
patient sequences, applying this pipeline, and physically applying the gRNAs to in vitro 
HIV-1-infected cell lines and ex vivo HIV-1-infected patient samples. This would parallel 
the work already performed to investigate excision potential, but targeted specifically for 
the HIV-1-infected cell line or primary cell population selected - hopefully yielding 
cutting efficiencies as projected by this pipeline in the post-excision resequenced cells.  
In addition, although we have proven the theoretical viability of using the CRISPR/Cas9 
gene-editing system to excise proviral HIV-1 DNA, we have not addressed methods of 
delivery and the unintended off-target effects that could result from the excision process. 
It has been mentioned that currently the CRISPR/Cas9 system is delivered primarily by 
viral vectors, which have been measured with up to 65% success in a diverse array of 
human somatic cells [17]. Although this is impressive, this is likely still not efficient 
enough to function as a vehicle for delivery for an absolute sterilizing cure, so work 
remains to be done. The viral vectors also are limited in the number of gRNAs that they 
can deliver based on the length of the vectors, with the current estimate landing around 7-
8 – this will also hopefully improve in due time [54]. The final concern of the application 
of this technology is in the possibility of off-target cuts or targeting sequences that occur 
naturally in the human genome. It is possible to perform BLAST queries to determine if a 
gRNA target sequence is in the human genome, however, the CRISPR/Cas9 system is 
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still an imperfect tool. There will always remain a probability of off target cleavages, 
however small, and despite the significant advancements that have already demonstrated 
whole exome sequencing with no off-target events in CRISPR/Cas9-modified human 
cells [7]. The results of this technical design project have also confirmed that due to the 
high conservation of the preferable LTR promotor target, that human transcription factor 
sequences often appear as gRNA targets. These sequences will need to be avoided when 
delivering the CRISPR/Cas9 system, either in administering the cure or by selecting the 
next most effective gRNA targets. It is possible to design 23-mer gRNAs that can use 
these roughly 10-mer human transcription factor sequences to increase binding affinity, 
but with the factors aligned with the least specific segments. This could cause for the 
more specific flank of the gRNA 23-mer to align with sequences that are hopefully virus-
specific and eliminate some probability of binding to the human genome. 
 Despite the challenges that surround the application of the CRISPR/Cas9 to 
excise HIV-1 proviral DNA, we have shown here that theoretically, excision can reach 
patient-specific 99.99% coverage. We have done so with one of the most variable virus 
species, and in the process established a bioinformatic pipeline that can continue to point 
us in the direction of optimizing delivery of these technologies as they continue to 
develop. The obstacles that remain in the evolution of these techniques are not likely to 
be insurmountable and, as a result, there is a realistic hope for excision of the entire HIV-
1 genome (in all quasispecies).  
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Chapter 3: Conclusions and Future Directions 
Conclusions and Future Directions 
 While the CRISPR/Cas9 gene-editing complex offers tremendous opportunity to 
treat one of the largest global epidemics, HIV-1 infection, further understanding of the 
underlying strategy to excise variable proviral DNA sequences from patients will open 
the door to a number of other viable applications. Because of their similarity in infection 
mechanisms and the dependence productive infectious production has on proviral DNA 
integration, it appears that the same techniques described here would be suitable to 
eradicate any other retroviruses including human T-lymphotropic virus (HTLV), and 
other viruses such as the herpes simplex virus (HSV).  
Due to the fact that retroviruses rely on the process of reverse transcription to 
replicate in an infected host, it becomes impossible for them maintain infection without 
the continual integration of proviral DNA into the host cell genome of newly infected 
cells. The hepatitis C virus relies on this mechanism to persist primarily in the liver of 
infected persons, causing scarring of the liver and cirrhosis that can develop into liver 
failure, liver cancer, or the sometimes terminal esophageal and gastric varices [55]. 
Similarly, the human T-lymphotropic virus family deploys this infection mechanism to 
serve as a virus cancer link for leukemia and several other diseases, with nearly 1 in 20 
infected persons developing leukemia from an infection [56]. The human foamy virus, or 
spumaviruses, is also thought to be a retrovirus using the same method of infection; it has 
been isolated from patients with primarily neoplastic and degenerative diseases including 
myasthenia gravis, multiple sclerosis, thyroiditis de Quervain, and Grave’s disease [57]. 
One of the most infectious family of viruses and most commonly sexually transmitted 
diseases is the herpes simplex virus 1 and 2, which produces many forms of cold sores 
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and genital herpes, respectively [58]. As neurotropic and neuroinvasive viruses, both the 
viruses hide from the immune system in the cell bodies of neurons based on the nuclear 
retention of the HSV genome in a nonintegrated unit-length circular DNA molecule [58]. 
With the ability to accurately sequence integrated viral genomes to determine all 
quasispecies, and the optimal gRNAs to cleave those proviral genomes from the host cell, 
it suggests that many viruses are viable opportunities to extend the techniques described 
to achieve viral eradication. As discussed earlier, what functions as a unique advantage 
when targeting viral DNA are the LTR regions at the beginning and ends of proviral 
DNA. Lucky, this benefit exists in all of these viruses, with the exception of HSV (type 
1) which still has repeat elements that would increase the probability of excision [59]. A 
brief analysis of reference LTR sequences provided by both the National Center for 
Biotechnology Information GenBank and the Los Alamos Hepatitis C Sequence and 
Immunology Database has shown that most of these viruses have comparable, if not 
many more, possible PAM targets in each region - showing that the CRISPR/Cas9 
excision technique may even be more successful when applied to these viruses. In 
addition, all of these viruses have significantly lower mutation rates (per nucleotide per 
year) when compared to HIV-1. This not only means that there is a substantially longer 
period to perform genotyping for a customized cure before quasispecies’ evolution would 
make a gRNA unusable, but it also implies that the inter-patient quasispecies variability 
may be lower and, as a result, the diversity of gRNAs required to excise would be less 
significant. The mutability of each virus, along with their respective LTR or repeat region 
estimated PAM targets can be seen in Table 1. 
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Table 1: A tabulated summation of each virus with their potential PAM targets and 
mutation rates. Gathered from numerous reference sequences and studies, the tabulated 
characteristics above represent the viability of the excision techniques described in this 
paper in respect to two critical attributes: number of PAM targets and viral mutation 
rates. Although the mutation rates appear to be large values, this is due to the application 
of a –log10 function to ease visibility. Mutation rates of the viruses per base, per year, for 
each virus are often extremely small numbers - with HIV-1, an extremely mutable virus, 
measuring at .009. As such, a smaller number above will correlate to a higher rate of 
mutation. It can be seen that HIV-1, although the primary focus of this design project, is 
one of the most difficult viruses to apply the excision technologies to. Thus, it becomes 
apparent that mastering these techniques with the HIV-1 virus would promise a great 
chance at success in the excision of its retroviral cousins. 
Virus LTR/Repeat Region 
Lengths 
Possible PAM 
Targets 
Mutation Rate 
(-log10) 
HCV 341 [60] 142 [60] 2.72 [61] 
HIV 654 [62] 170 [62] 2.05 [63] 
HFV 1769 [64] 314 [64] 7.77 [65] 
HSV 394, 8765, 6222 [66] 9777 [66] 6.86 [59] 
HTLV 757 [67] 276 [67] 7.33 [68] 
 
 
 
To better communicate the feasibility of each proviral excision using the 
CRISPR/Cas9 gene-editing system and the subsequent quasispecies genotyping and 
targeting provided by our bioinformatic pipeline, Figure 12 depicts each virus along with 
their respective estimated PAM targets and mutation rates. 
 
 
 
55 
 
 
Figure 12: A plot depicting the relative excision feasibility for each virus, the viruses 
further from the origin in Euclidean distance are anticipated to be the most difficult. 
In this plot, the x axis captures the –log10 mutation rate of each virus, with HIV-1 
displaying then the highest viral mutation rate. The y axis serves to communicate the 
possible number of PAM targets for each virus, which will show correlation to the 
number of cuts achievable with the delivery of a single gRNA. Both axes have been 
flipped to descending order and plotted in log form to communicate the difficulty of 
excision by distance from the origin. It can be inferred from this plot that HIV-1 is the 
most difficult to excise (by a small margin) whereas HSV is the least complicated. 
 
 
 
 As shown in in Figure 12, the methods and design in this journal are anticipated 
to be far more effective with other members of the retrovirus family, with the herpes 
simplex virus being the most attainable due to its sheer amount of PAM targets, trivial 
mutation rate, and its centralization neuron cell bodies which could serve to localize 
treatment and delivery. While they may appear to be more approachable applications of a 
sterilizing cure, none of these viruses pose as much of a threat to human life, and the 
quality thereof, than HIV-1. Due to the severity of prognosis when infected and sheer 
number of infected individuals, HIV-1 is a virus that demands attention and combative 
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measures be taken against its spread. What we have determined in this technical design 
project is that even with current technologies, a sterilizing cure of HIV-1, and many other 
retroviruses, may not be far off. In addition to increasingly effective, and less time 
consuming, sequencing methods, we already have precise gene editing techniques in 
practice that need only refinements, extremely precise and timely targeting, and proper 
vehicles for delivery. If the CRISPR/Cas 9 gene-editing system and related technologies 
continue to improve at the rate that we have seen, the bioinformatic pipeline described in 
this publication could serve to optimize the combative power of gene-editing therapeutics 
by elucidating retroviral quasispecies and determining exactly what targets will enhance 
excision. It is our hope that this information may facilitate HIV-1 excision from patients 
and prove that eradication of HIV-1 is no longer inconceivable. 
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